Oxford BioDynamics tech being used in US ALS study
Oxford Biodynamics
8.20p
16:40 25/04/24
Biotechnology company Oxford BioDynamics noted on Friday that Mitsubishi Tanabe Pharma America has announced that the first patient has been enrolled in the ‘REFINE-ALS’ clinical study.
FTSE AIM All-Share
753.12
16:50 25/04/24
The AIM-traded firm said the study was designed to identify and measure specific biomarkers and clinical assessments in up to 300 people with amyotrophic lateral sclerosis (ALS) in the United States, who had started treatment on ‘Radicava’ (edaravone).
“As part of the trial, Mitsubishi Tanabe Pharma America, its partners, and trial investigators, will use Oxford BioDynamics’ proprietary ‘EpiSwitch’ technology platform to assess the rate of ALS disease progression using highly novel epigenetic biomarkers,” the board explained in its short statement.